Enoch Paul*
The clinical care of neuroendocrine tumours (NETs), a rare neoplasm with rising prevalence, is difficult. The possibility for these tumours to emit amines or peptide hormones that result in recognisable clinical symptoms is an oddity (functioning tumors). Hormonal disorders can have a major detrimental impact on a patient's quality of life and prognosis. The attempts to understand the molecular pathways behind tumour growth and progression have been hampered by their relative rarity, vast anatomic distribution, and varied biological behaviour. Our knowledge of the genomic and epigenome events underlying NET pathogenesis has improved as a result of recent advancements in "omic" technology and their expanded accessibility.
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 